<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4394</journal-id><journal-id journal-id-type="pmc-domain">dadr</journal-id><journal-title-group><journal-title>Drug and Alcohol Dependence Reports</journal-title></journal-title-group><issn pub-type="epub">2772-7246</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12213302</article-id><article-id pub-id-type="pmcid-ver">PMC12213302.1</article-id><article-id pub-id-type="pmcaid">12213302</article-id><article-id pub-id-type="pmcaiid">12213302</article-id><article-id pub-id-type="pmid">40606797</article-id><article-id pub-id-type="doi">10.1016/j.dadr.2025.100349</article-id><article-id pub-id-type="pii">S2772-7246(25)00032-0</article-id><article-id pub-id-type="publisher-id">100349</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Full Length Report</subject></subj-group></article-categories><title-group><article-title>Factors associated with emergency room visits among patients with opioid use disorder: A study of buprenorphine-treated and untreated patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Gaiazov</surname><given-names initials="S">Sabrina</given-names></name><email>sabrina.gaiazov@Indivior.com</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Mullen</surname><given-names initials="W">William</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>Wheeler</surname><given-names initials="A">Ann</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Munnangi</surname><given-names initials="S">Swapna</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0025"><name name-style="western"><surname>Gu</surname><given-names initials="Y">Yifan</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0030"><name name-style="western"><surname>DeKoven</surname><given-names initials="M">Mitch</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0035"><name name-style="western"><surname>Dunne</surname><given-names initials="R">Robert</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><aff id="aff0005"><label>a</label>Indivior Inc., Medical Affairs, Richmond, VA, USA</aff><aff id="aff0010"><label>b</label>IQVIA Health Economics and Outcomes Research, Falls Church, VA, USA</aff><aff id="aff0015"><label>c</label>Department of Emergency Medicine, Wayne State University, Detroit, MI, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Correspondence to: Real-World Evidence. Medical Affairs North America, Indivior&#174; Inc.10710 Midlothian Turnpike, Suite 125, Richmond, VA 23235, USA. <email>sabrina.gaiazov@Indivior.com</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>6</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">490718</issue-id><elocation-id>100349</elocation-id><history><date date-type="received"><day>4</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-03 14:25:37.957"><day>03</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0005"><sec><title>Objective</title><p>Identify factors associated with 6-month emergency room (ER) outcomes in patients with opioid use disorder (OUD) and/or treated with buprenorphine (extended-release [BUP-XR] or transmucosal [BUP-TM]). Compare baseline characteristics and 6-month ER visits and healthcare resource utilization (HCRU) across treatment groups.</p></sec><sec><title>Methods</title><p>Patient claims data from September 2017&#8211; March 2022 were analyzed for patients diagnosed with OUD and/or treated with buprenorphine. Adjusted logistic regression models were used to identify factors associated with ER visits 6-months post-index.</p></sec><sec><title>Results</title><p>543 patients initiating BUP-XR, 52,569 BUP-TM and 57,125 patients with OUD diagnosis but no-medications for opioid use disorder (MOUD) were identified.</p><p>Patients who received BUP-XR (OR: 0.43, 95&#8201;% CI: 0.36&#8211;0.53) or BUP-TM (OR: 0.78; CI: 0.76&#8211;0.81) had lower odds for an all-cause post-index ER visit compared to those with no MOUD treatment.</p><p>Patients with later index years or those who had an opioid overdose ER visit in the baseline period had higher odds of post-index all-cause and opioid overdose ER visits.</p><p>1.2&#8201;% in BUP-TM cohort and 1&#8201;% in the no MOUD cohort had an opioid overdose ER visit, compared to 0&#8201;% in the BUP-XR cohort. The BUP-XR cohort had lower rates of inpatient stays, ER visits, and outpatient physician office visits compared to the BUP-TM and no MOUD cohorts but incurred higher pharmacy costs.</p></sec><sec><title>Conclusions</title><p>This study found that any buprenorphine treatment, particularly BUP-XR, was associated with lower odds of all-cause ER visits compared to patients with no MOUD, and highlighted potential risk factors that could help reduce the demand on ER services.</p></sec></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="li0005"><list-item id="u0005"><label>&#8226;</label><p id="p0005">Buprenorphine treatments linked to fewer ED visits compared to no MOUD.</p></list-item><list-item id="u0010"><label>&#8226;</label><p id="p0010">BUP-XR treated patients had lower inpatient/outpatient costs but higher pharmacy costs.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Prior overdose or comorbidities raise risk of ED utilization.</p></list-item></list></p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Emergency room visits</kwd><kwd>Opioid overdose</kwd><kwd>Opioid use disorder</kwd><kwd>Synthetic opioids</kwd><kwd>Buprenorphine</kwd><kwd>Patient costs</kwd><kwd>Medication for opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><sec id="sec0010"><label>1.1</label><title>Background</title><p id="p0020">The opioid crisis poses a growing public health challenge on a global scale, with increasing misuse, dependency, and mortality observed in various regions worldwide. Rates of opioid overdose in the United States (US) remain high level, with synthetic opioids being involved in 60&#8211;90&#8201;% of overdose deaths (<xref rid="bib15" ref-type="bibr">Schiller et al., 2023</xref>, <xref rid="bib4" ref-type="bibr">Centers for Disease Control and Prevention, 2022</xref>, <xref rid="bib10" ref-type="bibr">Garcia et al., 2022</xref>). Opioid overdose-related emergency room (ER) visits have become a critical aspect of this crisis; there are over 1000 ER visits everyday related to opioid misuse (<xref rid="bib15" ref-type="bibr">Schiller, Goyal et al., 2023</xref>). The emergence of synthetic opioids, such as fentanyl, has further exacerbated the situation, leading to a surge in ER visits related to opioid use disorder (OUD) (<xref rid="bib10" ref-type="bibr">Garcia, Stringfellow et al., 2022</xref>).</p><p id="p0025">Various treatment strategies, including buprenorphine in extended-release (BUP-XR) and transmucosal (BUP-TM) formulations, have been utilized to help address this urgent issue (2020). Comparing BUP-XR, BUP-TM, and patients with OUD with no medications for OUD (MOUD) patient groups is particularly relevant in understanding the relative effectiveness of these treatment strategies. BUP-XR offers sustained medication levels over time, potentially improving treatment adherence, whereas BUP-TM requires daily adherence, potentially influencing its overall impact (<xref rid="bib12" ref-type="bibr">Marsden et al., 2023</xref>). Furthermore, examining ER visits and related outcomes among patients with no MOUD allows for the evaluation of the benefits of any buprenorphine treatment relative to no MOUD, and provides insight into gaps in care. Understanding the effectiveness of these treatments in reducing ER visits can mitigate the strain on healthcare resources.</p></sec><sec id="sec0015"><label>1.2</label><title>Importance</title><p id="p0030">Previous studies demonstrated consensus among ER physicians regarding the initiation of buprenorphine for OUD treatment for patients with untreated OUD as the evidence-based recommendation (<xref rid="bib11" ref-type="bibr">Hawk et al., 2021</xref>, <xref rid="bib7" ref-type="bibr">Cowan et al., 2023</xref>). The National Institute on Drug Abuse (NIDA) Clinical Trials Network meeting in 2021 on advancing the initiation of buprenorphine for OUD in ERs identified research and knowledge gaps in eight categories, including interventions for ER staff and peers, out-of-hospital buprenorphine initiation, dosing and formulations of buprenorphine, linkage to care, scaling strategies, technology-based interventions, quality measures, and economic considerations (<xref rid="bib7" ref-type="bibr">Cowan et al., 2023</xref>). The participants of the NIDA meeting agreed that additional research is required to address these gaps and develop implementation strategies that can improve the adoption of buprenorphine in standard emergency care. However, there has not been extensive research investigating the factors that contribute to patients&#8217; ER utilization or comparing outcomes across different buprenorphine formulations. Understanding these differences, as well as the demographic and clinical characteristics and outcomes of patients presenting with OUD in emergency settings, is a critical area of investigation for improving patient outcomes and informing effective intervention strategies and policy decisions.</p></sec><sec id="sec0020"><label>1.3</label><title>Goals of this investigation</title><p id="p0035">This study aimed to:</p><p id="p0040">1. Examine the factors among patients with OUD that may be associated with ER visits among three patient treatment groups: patients treated with BUP-XR, patients treated with BUP-TM, and patients diagnosed with OUD with no MOUD.</p><p id="p0045">2. Compare baseline characteristics and 6-month outcomes (ER visits and HCRU) across the three patient treatment groups.</p></sec></sec><sec id="sec0025"><label>2</label><title>Methods</title><sec id="sec0030"><label>2.1</label><title>Data source and study design</title><p id="p0050">A retrospective cohort study was conducted using deidentified, deterministically linked patient data from IQVIA&#8217;s New Data Warehouse. It includes 1 billion Professional Fee Claims (Dx) per year, representing 60&#8211;70&#8201;% of physician activity in the US; more than 1.6 billion retail or mail-order Prescription Claims (LRx), representing dispensed prescriptions for approximately 85&#8201;% of all pharmacies in the US; and records from Hospital Charge Data Master (CDM) files from over 400 hospitals, covering 7 million annual inpatient stays and 60 million annual outpatient visits. IQVIA New Data Warehouse, extracts data from all healthcare channels in the US, including hospitals, providers (i.e. physicians, nurse practitioners), and pharmacies. Patient identifiers in all data sources are pre-processed using a proprietary, one-way encryption algorithm, so that patients may be linked across sources where patients overlap among data contributors. An internal protocol review committee consisting of non-author subject-matter experts reviewed the protocol prior to providing formal approval. Data complied with the Health Insurance Portability and Accountability Act (HIPAA). As this was a secondary analysis of a deidentified dataset, ethical review and approval were not required. The Department of Health and Human Services, as per exemption d(4) from 45 Code of Federal Regulations 46.104, does not consider analysis of deidentified secondary data to be human subjects research, and therefore this work was exempt from federal regulations of human subjects research. However, the protocol was submitted for internal review by subject matter experts not directly involved in the project, to confirm this work&#8217;s exemption.</p></sec><sec id="sec0035"><label>2.2</label><title>Study population</title><p id="p0055">Adults &#8805;&#8201;18 years with &#8805;&#8201;1 medical or pharmacy claim for buprenorphine (BUP-XR and BUP-TM) identified via National Drug Codes (NDC) and Healthcare Common Procedure Coding System (HCPCS) codes in Dx or LRx or &#8805;&#8201;1 medical claim with an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis of opioid use disorder (OUD) (<xref rid="sec0135" ref-type="sec">Supplemental Table 1</xref>) in Dx between March 1, 2018 to September 30, 2021 were selected. The index date was the first claim of corresponding form of buprenorphine (BUP-XR or BUP-TM) for the two buprenorphine cohorts. For the remaining patients, the date of the first OUD diagnosis was selected as the index date. Patients were required to have linkage to and activity in Dx and LRx (&#8805;1 claim in LRx and Dx) and a stable pharmacy data source, meaning that the patient&#8217;s most frequently visited pharmacy maintained consistent data reporting in the 6-month baseline and post-index periods. Specifically, the pharmacy&#8217;s total weekly volume of prescription could not fall below 50&#8201;% of the median volume recorded over the prior 10 weeks in the 6-month baseline and post-index periods. This was to ensure stability of data at the pharmacy level and reduce missingness, as pharmacies that did not have stable reporting may lead to misclassification of prescriptions during the risk period. This process resulted in 6.9&#8201;% of the sample being excluded at this stage. Linkage to CDM at any point during the study period was also required. Patients with any of the following were excluded: 1) having naltrexone, methadone, or a single-ingredient buprenorphine product indicated for moderate to severe chronic pain (Belbuca, Buprenex, or Butrans etc.), identified via NDC or HCPCS codes, during the post-index 2) a diagnosis requiring chronic opioid treatment for pain in the baseline period or with significant traumatic injury or a major surgical procedure within 30 days prior to the index date 3) an invalid year of birth or gender. Patients in the BUP-XR cohort with BUP-TM or BUP-XR implants (Probuphine) during the post-index period were excluded. Patients in the BUP-TM cohort with BUP-XR during the post-index period were excluded. Patients with OUD who had BUP-TM or BUP-XR during the post-index period were excluded from the no MOUD treatment cohort. Given the study aimed to focus on identifying differences between BUP-XR and BUP-TM, rather than buprenorphine treatment in general, patients with overlapping treatment regimens were removed to isolate treatment effects for valid comparison between groups.</p></sec><sec id="sec0040"><label>2.3</label><title>Study measures</title><p id="p0060">Patient demographics and physician specialty of the MOUD prescriber were assessed on the index date. At the 6-month baseline, clinical characteristics including the Charlson Comorbidity Index (CCI) (Dartmouth-Manitoba adaptation) (<xref rid="bib13" ref-type="bibr">Romano et al., 1993</xref>) and comorbidities were assessed in both CDM and Dx. Baseline drug use (benzodiazepines, naloxone, opioids, synthetic opioids) was identified via NDC and HCPCS codes in LRx and Dx, respectively. HCRU and total costs were also assessed over the baseline period using CDM, Dx, and LRx.</p><p id="p0065">Outcomes were assessed during the 6-month post-index period. The primary outcomes were four emergency room (ER) visit types: all-cause, opioid overdose-related, synthetic opioid overdose-related, and opioid withdrawal/detoxification (<xref rid="sec0135" ref-type="sec">Supplemental Table 1</xref>). Post-index all-cause HCRU and costs were also assessed.</p></sec><sec id="sec0045"><label>2.4</label><title>Statistical analysis</title><p id="p0070">Descriptive statistics were reported for baseline demographic, clinical characteristics and outcome measures by treatment cohort (BUP-XR vs. BUP-TM; BUP-TM vs. no MOUD; BUP-XR vs. no MOUD treatment). Independent comparisons between groups were conducted using t-tests for means and chi-square and Fisher&#8217;s exact test (if needed) for categorical variables.</p><p id="p0075">Multivariable logistic regression models were used to examine associations between baseline characteristics and the four ER visit types. Regression models were adjusted for patient demographics (age group, gender, geographic region, payer type, index year), clinical characteristics (CCI, comorbidities, medications), and pre-index ER visit related to an opioid overdose. Bivariable associations with the baseline measures and four outcomes were assessed, and significant variables at the bivariable level were considered in the final models. Bivariable associations, collinearity assessment, and clinical judgement, by researchers who have worked directly with patients receiving MOUD, about potential confounding factors were used to determine variables included in the final model. In cases where quasi-complete separation of variables and outcomes occurred, a &#8220;do nothing&#8221; approach was taken, and odds ratios and test statistics were only reported for covariates where the maximum likelihood estimates existed (<xref rid="bib1" ref-type="bibr">Allison, 2008</xref>). Missingness was handled by creating an &#8220;Unknown&#8221; category for relevant variables and included in analysis. A p-value of &lt;&#8201;0.05 was considered statistically significant for the descriptive statistics for baseline demographic, clinical characteristics and outcome measures by treatment groups. Bonferroni correction was applied to adjust for multiple comparisons in the adjusted logistic regression model (<xref rid="bib8" ref-type="bibr">Dunn, 1961</xref>). After applying the Bonferroni correction, the statistically significant p-value for the adjusted multivariable logistic regressions examining associations across ER visit types was 0.001.</p><p id="p0080">Analyses were conducted using SAS Release 9.4 (SAS Institute Inc., Cary, NC).</p></sec></sec><sec id="sec0050"><label>3</label><title>Results</title><sec id="sec0055"><label>3.1</label><title>Study population and baseline characteristics</title><p id="p0085">543 patients initiating BUP-XR, 52,569 patients initiating BUP-TM, and 57,125 patients with OUD but with no MOUD treatment were identified, resulting in a total study population of 110,237 patients (<xref rid="sec0135" ref-type="sec">Supplemental Figure 1</xref>). Among patients without MOUD, the most common index year was 2018 (38.8&#8201;%, n&#8201;=&#8201;22,192) and only 14.9&#8201;% (n&#8201;=&#8201;8525) had an index year of 2021. Among those with BUP-XR, there was an opposite pattern: only 7.4&#8201;% (n&#8201;=&#8201;40) had an index year of 2018, and 30.2&#8201;% (n&#8201;=&#8201;164) had an index year of 2021. And patients with BUP-TM primarily had an index year of 2018 (54.5&#8201;%, n&#8201;=&#8201;28,624). On average, patients in the BUP-XR cohort were 34.3 years (standard deviation [SD]: 9.6) while patients in the BUP-TM (mean: 40.0 years [SD: 12.9]) and no MOUD treatment cohorts (50.4 years [17.9]) were significantly older. There was a significantly higher proportion of males in the BUP-XR cohort compared to the BUP-TM (60&#8201;% vs. 52&#8201;%, p&#8201;&lt;&#8201;0.01) and no MOUD treatment (60&#8201;% vs. 45&#8201;%, p&#8201;&lt;&#8201;0.01) cohorts. Additionally, there were more BUP-XR patients with third-party payer insurance (76&#8201;%) than in the BUP-TM (68&#8201;%) and no MOUD treatment cohorts (68&#8201;%). There was a significantly higher proportion of patients prescribed BUP-XR with baseline anxiety, depression, hepatitis, non-opioid substance use disorder (SUD), post-traumatic stress disorder (PTSD) and evidence of smoking compared to the BUP-TM (all p&#8201;&lt;&#8201;0.05) and no MOUD treatment cohorts (all p&#8201;&lt;&#8201;0.01). Compared to BUP-TM or no MOUD treatment cohorts, there was a higher proportion of patients in the BUP-XR cohort with a baseline naloxone prescription or administration (BUP-XR: 14&#8201;%, BUP-TM: 6&#8201;%, No MOUD: 3&#8201;%) and a lower proportion with a baseline opioid (7&#8201;% vs. 19&#8201;% vs 46&#8201;%). During the 6-month baseline period prior to treatment initiation, a significantly higher proportion of patients in the BUP-XR cohort had an ER opioid overdose visit compared to the BUP-TM (3&#8201;% vs. 2&#8201;%, p&#8201;=&#8201;0.02) and no MOUD treatment (3&#8201;% vs. 1&#8201;%, p&#8201;&lt;&#8201;0.001) cohorts. Baseline total all-cause costs were also higher in the BUP-XR cohort compared to the BUP-TM ($9367 [$16,753]) vs. $6210 [$18,607] and no MOUD treatment ($9367 [$16,753] vs. $6871 [19,628]) cohorts. Missingness in the overall sample was low across all variables, except for reported physician specialty. Among patients without MOUD prescriptions, 18,267 (32.0&#8201;%) had unknown or missing values for this variable. For participants with BUP-XR, 91 (16.7&#8201;%) participants and for participants with BUP-TM, 3404 (6.5&#8201;%) had missing or unknown values for physician specialty (<xref rid="tbl0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 1</label><caption><p>Demographics and baseline (6-months) clinical characteristics among patients with BUP-XR, BUP, or no MOUD.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Demographics and Baseline Clinical Characteristics</bold></th><th align="left" colspan="1" rowspan="1"/><th align="left" rowspan="2" colspan="1"><bold>BUP-TM</bold><break/><bold>(N&#8201;=&#8201;52,569)</bold></th><th align="left" rowspan="2" colspan="1"><bold>OUD with No MOUD</bold><break/><bold>(N&#8201;=&#8201;57,125)</bold></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold></th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>BUP-XR</bold><break/><bold>(N&#8201;=&#8201;543)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to BUP-TM)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to No Tx)</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Demographics</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Age in years (mean, SD)</bold></td><td align="left" colspan="1" rowspan="1">34.3 (9.6)</td><td align="left" colspan="1" rowspan="1">40 (12.9)</td><td align="left" colspan="1" rowspan="1">50.4 (17.9)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><bold>Age group (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">18&#8211;34 years</td><td align="left" colspan="1" rowspan="1">315 (58.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">21,459 (40.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,145 (24.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">35&#8211;44 years</td><td align="left" colspan="1" rowspan="1">154 (28.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,561 (27.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">8882 (15.5&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">45&#8211;54 years</td><td align="left" colspan="1" rowspan="1">51 (9.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">7981 (15.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">8519 (14.9&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">55&#8211;64 years</td><td align="left" colspan="1" rowspan="1">19 (3.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">6139 (11.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">11,318 (19.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">65&#8211;74 years</td><td align="left" colspan="1" rowspan="1">2 (0.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">1863 (3.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">8769 (15.4&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;75 years</td><td align="left" colspan="1" rowspan="1">2 (0.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">566 (1.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">5492 (9.6&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Gender (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">328 (60.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">27,264 (51.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">25,941 (45.4&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">215 (39.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">25,305 (48.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">31,184 (54.6&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Geographic region (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Northeast</td><td align="left" colspan="1" rowspan="1">141 (26.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">17,116 (32.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">11,312 (19.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Midwest</td><td align="left" colspan="1" rowspan="1">61 (11.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">7058 (13.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">7780 (13.6&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">South</td><td align="left" colspan="1" rowspan="1">192 (35.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">17,952 (34.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">23,069 (40.4&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">West</td><td align="left" colspan="1" rowspan="1">117 (21.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">9796 (18.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,964 (26.2&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Unknown/Missing</td><td align="left" colspan="1" rowspan="1">32 (5.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">647 (1.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">(0.0&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Payer type (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.009</td><td align="char" colspan="1" rowspan="1">0.021</td></tr><tr><td colspan="1" rowspan="1">Cash</td><td align="left" colspan="1" rowspan="1">15 (2.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">2770 (5.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">876 (1.5&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Medicaid</td><td align="left" colspan="1" rowspan="1">96 (17.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">8291 (15.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">3255 (5.7&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Medicare</td><td align="left" colspan="1" rowspan="1">18 (3.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">5911 (11.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,158 (24.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Third party</td><td align="left" colspan="1" rowspan="1">414 (76.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">35,597 (67.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">38,805 (67.9&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Other/Missing</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">(0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">31 (0.1&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Index Year (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">40 (7.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">28,624 (54.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">22,192 (38.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">137 (25.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">9671 (18.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,597 (25.6&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">202 (37.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">8396 (16.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">11,811 (20.7&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">164 (30.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">5878 (11.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">8525 (14.9&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Clinical characteristics</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Physician specialty (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.022</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Family Medicine</td><td align="left" colspan="1" rowspan="1">94 (17.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">11,225 (21.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">5980 (10.5&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Internal Medicine</td><td align="left" colspan="1" rowspan="1">40 (7.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">6874 (13.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">5657 (9.9&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Nurse Practitioner</td><td align="left" colspan="1" rowspan="1">141 (26.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">7615 (14.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">4210 (7.4&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Other Reported Specialty</td><td align="left" colspan="1" rowspan="1">177 (32.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">23,451 (44.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">23,011 (40.3&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Unknown/Missing</td><td align="left" colspan="1" rowspan="1">91 (16.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">3404 (6.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">18,267 (32.0&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Charlson Comorbidity Index (CCI) (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.015</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">478 (88.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">44,272 (84.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">38,072 (66.6&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">47 (8.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">5545 (10.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">9606 (16.8&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">9 (1.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">1499 (2.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">4536 (7.9&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2 (0.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">480 (0.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">1989 (3.5&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">4&#8201;+</td><td align="left" colspan="1" rowspan="1">7 (1.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">773 (1.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">2922 (5.1&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Comorbidities of interest (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Anxiety disorder</td><td align="left" colspan="1" rowspan="1">162 (29.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">10,905 (20.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">10,033 (17.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Cardiac arrhythmia</td><td align="left" colspan="1" rowspan="1">10 (1.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">1011 (1.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">2767 (4.8&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.891</td><td align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Cardiac valvular disease</td><td align="left" colspan="1" rowspan="1">3 (0.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">413 (0.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">1014 (1.8&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.805</td><td align="char" colspan="1" rowspan="1">0.031</td></tr><tr><td colspan="1" rowspan="1">Cerebrovascular disease</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">287 (0.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">1122 (2.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.128</td><td align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Chronic pain/Fibromyalgia</td><td align="left" colspan="1" rowspan="1">6 (1.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">334 (0.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">395 (0.7&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.168</td><td align="char" colspan="1" rowspan="1">0.287</td></tr><tr><td colspan="1" rowspan="1">Dementia/Alzheimer's</td><td align="left" colspan="1" rowspan="1">2 (0.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">150 (0.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">547 (1.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.671</td><td align="char" colspan="1" rowspan="1">0.159</td></tr><tr><td colspan="1" rowspan="1">Depression</td><td align="left" colspan="1" rowspan="1">144 (26.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">10,161 (19.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">10,089 (17.7&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Dyslipidemia</td><td align="left" colspan="1" rowspan="1">22 (4.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">2714 (5.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">8550 (15.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.244</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Epilepsy/Seizure disorder</td><td align="left" colspan="1" rowspan="1">11 (2.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">1152 (2.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">1363 (2.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.793</td><td align="char" colspan="1" rowspan="1">0.584</td></tr><tr><td colspan="1" rowspan="1">Hepatitis</td><td align="left" colspan="1" rowspan="1">60 (11.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">3547 (6.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">2346 (4.1&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">HIV/AIDS</td><td align="left" colspan="1" rowspan="1">5 (0.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">427 (0.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">621 (1.1&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.633</td><td align="char" colspan="1" rowspan="1">0.710</td></tr><tr><td colspan="1" rowspan="1">Liver/GB/Pancreatic disease</td><td align="left" colspan="1" rowspan="1">6 (1.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">1122 (2.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">1945 (3.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.098</td><td align="char" colspan="1" rowspan="1">0.003</td></tr><tr><td colspan="1" rowspan="1">Metabolic syndrome</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">43 (0.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">101 (0.2&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">Myocardial infarction/CAD</td><td align="left" colspan="1" rowspan="1">5 (0.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">778 (1.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">3032 (5.3&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.282</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Non-opioid SUD</td><td align="left" colspan="1" rowspan="1">307 (56.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">19,777 (37.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">16,090 (28.2&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Osteoarthritis</td><td align="left" colspan="1" rowspan="1">3 (0.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">1248 (2.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">5804 (10.2&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.005</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Paralysis</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">140 (0.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">501 (0.9&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.410</td><td align="char" colspan="1" rowspan="1">0.017</td></tr><tr><td colspan="1" rowspan="1">Peptic ulcer</td><td align="left" colspan="1" rowspan="1">1 (0.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">149 (0.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">238 (0.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">0.732</td></tr><tr><td colspan="1" rowspan="1">Peripheral vascular disease</td><td align="left" colspan="1" rowspan="1">1 (0.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">243 (0.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">1498 (2.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.527</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">PTSD</td><td align="left" colspan="1" rowspan="1">45 (8.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">2528 (4.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">2142 (3.7&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.000</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Rheumatologic disease</td><td align="left" colspan="1" rowspan="1">24 (4.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">2562 (4.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">8520 (14.9&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.625</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Schizophrenia</td><td align="left" colspan="1" rowspan="1">12 (2.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">1107 (2.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">2035 (3.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.867</td><td align="char" colspan="1" rowspan="1">0.090</td></tr><tr><td colspan="1" rowspan="1">Sleep disorders</td><td align="left" colspan="1" rowspan="1">41 (7.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">3211 (6.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">4929 (8.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.163</td><td align="char" colspan="1" rowspan="1">0.373</td></tr><tr><td colspan="1" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">103 (19.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">8265 (15.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">7462 (13.1&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.039</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Thyroid disease</td><td align="left" colspan="1" rowspan="1">12 (2.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">1563 (3.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">3454 (6.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.297</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><bold>Medications of interest (n, %)</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Benzodiazepines</td><td align="left" colspan="1" rowspan="1">104 (19.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">11,591 (22.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,174 (24.8&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.105</td><td align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td align="left" colspan="1" rowspan="1">78 (14.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">3308 (6.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">1487 (2.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Opioids</td><td align="left" colspan="1" rowspan="1">40 (7.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">9971 (19.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">26,434 (46.3&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Synthetic opioids</td><td align="left" colspan="1" rowspan="1">10 (1.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">2828 (5.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">6664 (11.7&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.000</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><bold>Baseline HCRU and Cost</bold></td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit (all cause) (n, %)</td><td align="left" colspan="1" rowspan="1">169 (31.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,355 (27.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,535 (25.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.047</td><td align="char" colspan="1" rowspan="1">0.003</td></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit related to an opioid overdose (n, %)</td><td align="left" colspan="1" rowspan="1">15 (2.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">810 (1.5&#8201;%)</td><td align="left" colspan="1" rowspan="1">410 (0.7&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.022</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201; Inpatient hospitalization (n, %)</td><td align="left" colspan="1" rowspan="1">23 (4.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">2293 (4.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">2172 (3.8&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.886</td><td align="char" colspan="1" rowspan="1">0.599</td></tr><tr><td colspan="1" rowspan="1">Total all-cause costs (mean, SD)</td><td align="left" colspan="1" rowspan="1">$9367 ($16,753)</td><td align="left" colspan="1" rowspan="1">$6210 ($18,607)</td><td align="left" colspan="1" rowspan="1">$6871 ($19,628)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AIDS=&#8201; acquired immunodeficiency syndrome; BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; CAD=&#8201; coronary artery disease; CCI=&#8201; Charlson Comorbidity Index; ER=&#8201; emergency room; GB=&#8201; gallbladder; HIV=&#8201; human immunodeficiency virus; OUD=&#8201; opioid use disorder; PTSD=&#8201; post-traumatic stress disorder; SD=&#8201; standard deviation; SUD=&#8201; substance use disorder; MOUD =&#8201; medications for opioid use disorder</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec0060"><label>3.2</label><title>All-Cause ER visit</title><p id="p0090">Across treatment groups, 27.8&#8201;% of BUP-XR, 35.7&#8201;% of BUP-TM, and 37.4&#8201;% of no MOUD treatment patients had an all-cause ER visit. (<xref rid="tbl0010" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl0010" orientation="portrait"><label>Table 2</label><caption><p>Post-index (6-months) ER visits outcomes among patients with BUP-XR, BUP-TM, or no treatment for OUD.</p></caption><alt-text id="at0010">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>ER Visit Outcomes</bold></th><th align="left" colspan="1" rowspan="1"><hr/></th><th align="left" rowspan="2" colspan="1"><bold>BUP-TM</bold><break/><bold>(N&#8201;=&#8201;52,569)</bold></th><th align="left" rowspan="2" colspan="1"><bold>OUD with No MOUD</bold><break/><bold>(N&#8201;=&#8201;57,125)</bold></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold><hr/></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold><hr/></th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>BUP-XR</bold><break/><bold>(N&#8201;=&#8201;543)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to BUP-TM)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to No Tx)</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit (all-cause) (n, %)</td><td align="left" colspan="1" rowspan="1">151 (27.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">18,767 (35.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">21,343 (37.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit for an opioid overdose (n, %)</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">629 (1.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">578 (1.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.010</td><td align="char" colspan="1" rowspan="1">0.019</td></tr><tr><td colspan="1" rowspan="1">Substance associated with the first ER opioid overdose (n, %)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Opium</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">2 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">6 (0.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">Heroin</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">303 (0.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">221 (0.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.081</td><td align="char" colspan="1" rowspan="1">0.280</td></tr><tr><td colspan="1" rowspan="1">Natural or semi-synthetic opioids</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">203 (0.4&#8201;%)</td><td align="left" colspan="1" rowspan="1">232 (0.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.279</td><td align="char" colspan="1" rowspan="1">0.287</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">1 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">9 (0.0&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">Synthetic opioids, other than methadone</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">73 (0.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">68 (0.1&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">Other unspecified narcotic</td><td align="left" colspan="1" rowspan="1">0 (0.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">85 (0.2&#8201;%)</td><td align="left" colspan="1" rowspan="1">74 (0.1&#8201;%)</td><td align="char" colspan="1" rowspan="1">1.000</td><td align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit for opioid withdrawal/detoxification (n, %)</td><td align="left" colspan="1" rowspan="1">4 (0.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">689 (1.3&#8201;%)</td><td align="left" colspan="1" rowspan="1">330 (0.6&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.241</td><td align="char" colspan="1" rowspan="1">0.562</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; ER=&#8201; emergency room; OUD=&#8201; opioid use disorder; MOUD =&#8201; medications for opioid use disorder</p></fn></table-wrap-foot></table-wrap></p><p id="p0095">Those that received BUP-XR (Odds Ratio [OR]: 0.43, 95&#8201;% Confidence Interval [CI]: 0.36&#8211;0.53) or BUP-TM (OR: 0.78; 95&#8201;% CI: 0.76&#8211;0.81) had lower odds of an all-cause post-index ER visit than those with no MOUD treatment. Additionally, those with later index years (reference: 2018) had higher odds of an all-cause ER visit (2019 OR: 1.22 (CI: 1.18&#8211;1.26), 2020 OR: 1.14 (CI: 1.10&#8211;1.18), 2021 OR:1.15 (CI: 1.11&#8211;1.20)). Those with a &#8805;&#8201;1 claim in the baseline period for a benzodiazepine (OR: 1.09, CI: 1.06&#8211;1.12), naloxone (OR: 1.21, CI: 1.14&#8211;1.29), or an ER visit for an opioid overdose (OR: 1.48, CI: 1.32&#8211;1.67) had higher odds of an all-cause ER visit while those with &#8805;&#8201;1 claim for a synthetic opioid in the baseline period (OR: 0.91, CI: 0.86&#8211;0.95) had lower odds of an all-cause ER visit (<xref rid="fig0005" ref-type="fig">Fig. 1</xref><bold>,</bold>
<xref rid="sec0135" ref-type="sec">Supplemental Table 2</xref>).<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Adjusted logistic regression models examining associations between baseline characteristics and an all-cause post-index ER visit within the 6-month post-index period among patients with BUP-XR, BUP-TM, or no MOUD. Abbreviations: BUP=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; CCI=&#8201; charlson comorbidity index; CI=&#8201; confidence interval; ER=&#8201; emergency room; GB=&#8201; gallbladder; HCRU=&#8201; healthcare resource utilization; MOUD =&#8201; medications for opioid use disorder; OUD=&#8201; opioid use disorder; PTSD=&#8201; post-traumatic stress disorder; ref=&#8201; reference; SUD=&#8201; substance use disorder.</p></caption><alt-text id="at0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec0065"><label>3.3</label><title>ER visit for opioid overdose</title><p id="p0100">Across treatment groups, 0&#8201;% of BUP-XR, 1.2&#8201;% of BUP-TM, and 1.0&#8201;% of patients without MOUD treatment had &#8805;&#8201;1 opioid overdose ER visit (<xref rid="tbl0010" ref-type="table">Table 2</xref>).</p><p id="p0105">Patients in the BUP-TM cohort had lower odds of an opioid overdose ER visit in the post index period compared to the no-treatment cohort (OR: 0.77, CI: 0.68&#8211;0.88). Males (reference: females) (OR: 1.64, CI: 1.46&#8211;1.85), and those with later index years (reference: 2018) (2019 OR: 1.36 (CI: 1.17&#8211;1.59), 2020 OR: 1.72 (CI: 1.48&#8211;2.00), 2021 OR: 1.43 (CI: 1.20&#8211;1.72) had higher odds of a post-index ER visit for opioid overdose. Patients with &#8805;&#8201;1 claim for naloxone (OR: 1.55, CI: 1.26&#8211;1.89) and &#8805;&#8201;1 ER visit related to an opioid overdose in the baseline period (OR: 5.61, CI: 4.54&#8211;6.94) had higher odds of an ER visit for opioid overdose (<xref rid="fig0010" ref-type="fig">Fig. 2</xref><bold>,</bold>
<xref rid="sec0135" ref-type="sec">Supplemental Table 3</xref>).<fig id="fig0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Adjusted logistic regression models examining associations between baseline characteristics and a post-index ER visit for an opioid overdose within the 6-month post-index period among patients with BUP-XR, BUP-TM, or no MOUD*. Abbreviations: BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; CAD=&#8201; coronary artery disease; CCI=&#8201; charlson comorbidity index; CI=&#8201; confidence interval; ER=&#8201; emergency room; HCRU=&#8201; healthcare resource utilization; OUD=&#8201; opioid use disorder; ref=&#8201; reference; SUD=&#8201; substance use disorder; MOUD =&#8201; medications for opioid use disorder *BUP-XR is not present in the figure as there were no post-index ER visits for opioid overdose among the BUP-XR patient group.</p></caption><alt-text id="at0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0010" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec0070"><label>3.4</label><title>ER visit for synthetic opioid overdose</title><p id="p0110">Across treatment groups, 0&#8201;% of BUP-XR, 0.1&#8201;% of BUP-TM, and 0.1&#8201;% of no MOUD treatment had a synthetic opioid overdose ER visit (<xref rid="tbl0010" ref-type="table">Table 2</xref>).</p><p id="p0115">Those with index years in 2020 (OR: 2.28, CI: 1.40&#8211;3.70) or 2021 (OR: 4.62, CI: 2.94&#8211;7.27) (reference: 2018) had higher odds of a post-index ER visit for synthetic opioid overdose. Those with &#8805;&#8201;1 claim for an ER visit for opioid overdose in the baseline period (OR: 4.46, CI: 2.52&#8211;7.88) had higher odds of an ER visit for synthetic opioid overdose (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>, <xref rid="sec0135" ref-type="sec">Supplemental Table 4</xref>).<fig id="fig0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Adjusted logistic regression models examining associations between baseline characteristics and a post-index ER visit for a synthetic opioid overdose within the 6-month post-index period among patients with BUP-XR, BUP-TM, or no MOUD. * abbreviations: BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; CCI=&#8201; charlson comorbidity index; CI=&#8201; confidence interval; ER=&#8201; emergency room; HCRU=&#8201; healthcare resource utilization; OUD=&#8201; opioid use disorder; ref=&#8201; reference; SUD=&#8201; substance use disorder; MOUD =&#8201; medications for opioid use disorder *BUP-XR is not present in the figure as there were no post-index ER visits for opioid withdrawal/detoxification among the BUP-XR patient group.</p></caption><alt-text id="at0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0015" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec0075"><label>3.5</label><title>ER visit for Withdrawal/Detoxification</title><p id="p0120">Across treatment groups, 0.7&#8201;% of BUP-XR, 1.3&#8201;% of BUP-TM, and 0.6&#8201;% of no MOUD treatment patients had an ER visit for opioid withdrawal/detoxification (<xref rid="tbl0010" ref-type="table">Table 2</xref>). As observed in other types of ER visits, patients with later index years (compared to 2018) and those with &#8805;&#8201;1 claim for an ER visit for opioid overdose in the baseline period (OR: 1.69, CI: 1.17&#8211;2.44) had higher odds of a post-index ER visit for opioid withdrawal/detoxification. Those with BUP-TM (OR: 1.77, 95&#8201;% CI: 1.53&#8211;2.06) were more likely to have an ER visit for opioid withdrawal/detoxification than those with no MOUD treatment while there was no significant difference for those with BUP-XR (OR: 0.70, 95&#8201;% CI: 0.26&#8211;1.89) compared to no MOUD treatment. (<xref rid="fig0020" ref-type="fig">Fig. 4</xref><bold>;</bold>
<xref rid="sec0135" ref-type="sec">Supplemental Table 5</xref>).<fig id="fig0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Adjusted logistic regression models examining associations between baseline characteristics and a post-index ER visit for opioid detoxification/withdrawal within the 6-month post-index period among patients with BUP-XR, BUP-TM, or no MOUD. Abbreviations: BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; CAD=&#8201; coronary artery disease; CCI=&#8201; charlson comorbidity index; HCRU=&#8201; healthcare resource utilization; OUD=&#8201; opioid use disorder; ref=&#8201; reference; SUD=&#8201; substance use disorder; MOUD =&#8201; medications for opioid use disorder.</p></caption><alt-text id="at0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk0020" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec0080"><label>3.6</label><title>Healthcare resource utilization and cost across treatment groups</title><p id="p0125">Compared to BUP-TM, lower proportion of patients in the BUP-XR cohort had an inpatient stay (3&#8201;% vs. 5&#8201;%), ER visit (28&#8201;% vs. 36&#8201;%), or outpatient physician office visit (60&#8201;% vs. 67&#8201;%) in the 6-month post-index period. Similarly, a lower proportion of patients in the BUP-XR cohort had an inpatient stay (3&#8201;% vs. 10&#8201;%), ER visit (28&#8201;% vs. 37&#8201;%), and outpatient physician office visit (60&#8201;% vs. 72&#8201;%) than patients in the no MOUD cohort.</p><p id="p0130">The BUP-XR cohort had significantly lower inpatient costs (mean [SD]: $282 [$2147]) compared to both BUP-TM ($1404 [$12,536]) and no MOUD cohorts ($3336 [$20,211]). Additionally, patients with BUP-XR had significantly lower outpatient medical costs ($4184 [$8882]) compared to patients with no MOUD ($7639 [$20,046]).</p><p id="p0135">The BUP-XR cohort had similar overall all-cause costs ($12,995 [$15,184]) as the no MOUD cohort ($13,623 [$34,401]). While the BUP-XR cohort had significantly higher overall costs compared to the BUP-TM cohort ($8733 [$21,538]), this was primarily driven by significantly higher outpatient pharmacy costs in the BUP-XR cohort ($8531 [$11,540]) compared to the BUP-TM cohort ($3461 [$9149]). It was not possible to determine if the BUP-XR medication itself was driving this difference. <bold>(</bold><xref rid="tbl0015" ref-type="table">Table 3</xref><bold>)</bold><table-wrap position="float" id="tbl0015" orientation="portrait"><label>Table 3</label><caption><p>Post-index (6-months) HCRU and healthcare costs among patients with BUP-XR, BUP-TM, or no treatment for OUD.</p></caption><alt-text id="at0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><bold>Post-Index HCRU/Cost</bold></th><th colspan="1" rowspan="1"><hr/></th><th align="left" rowspan="2" colspan="1"><bold>BUP-TM</bold><break/><bold>(N&#8201;=&#8201;52,569)</bold></th><th align="left" rowspan="2" colspan="1"><bold>OUD with No Tx</bold><break/><bold>(N&#8201;=&#8201;57,125)</bold></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold><hr/></th><th align="left" colspan="1" rowspan="1"><bold>p-value</bold><hr/></th></tr><tr><th align="left" colspan="1" rowspan="1"><bold>BUP-XR</bold><break/><bold>(N&#8201;=&#8201;543)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to BUP-TM)</bold></th><th align="left" colspan="1" rowspan="1"><bold>(BUP-XR to No Tx)</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>HCRU per patient</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><underline>Inpatient stay</underline></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 inpatient stay (n, %)</td><td align="left" colspan="1" rowspan="1">15 (2.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">2702 (5.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">5399 (9.5&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.012</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Average length of stay in days (mean, SD)</td><td align="left" colspan="1" rowspan="1">5.4 (2.8)</td><td align="left" colspan="1" rowspan="1">6.0 (6.3)</td><td align="left" colspan="1" rowspan="1">6.2 (5.7)</td><td align="char" colspan="1" rowspan="1">0.720</td><td align="char" colspan="1" rowspan="1">0.597</td></tr><tr><td colspan="1" rowspan="1">Number of hospitalizations (mean, SD)</td><td align="left" colspan="1" rowspan="1">0.0 (0.2)</td><td align="left" colspan="1" rowspan="1">0.1 (0.3)</td><td align="left" colspan="1" rowspan="1">0.1 (0.5)</td><td align="char" colspan="1" rowspan="1">0.014</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><underline>Outpatient medical</underline></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 ER visit (n, %)</td><td align="left" colspan="1" rowspan="1">151 (27.8&#8201;%)</td><td align="left" colspan="1" rowspan="1">18,767 (35.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">21,343 (37.4&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Number of ER visits (mean, SD)</td><td align="left" colspan="1" rowspan="1">0.5 (1.1)</td><td align="left" colspan="1" rowspan="1">0.7 (1.3)</td><td align="left" colspan="1" rowspan="1">0.8 (1.6)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Physician office visits</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 physician office visit (n, %)</td><td align="left" colspan="1" rowspan="1">324 (59.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">35,184 (66.9&#8201;%)</td><td align="left" colspan="1" rowspan="1">40,836 (71.5&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Number of physician office visits (mean, SD)</td><td align="left" colspan="1" rowspan="1">3.3 (5.5)</td><td align="left" colspan="1" rowspan="1">4.7 (7.4)</td><td align="left" colspan="1" rowspan="1">4.2 (6.4)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Laboratory/Pathology tests</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 lab/pathology test (n, %)</td><td align="left" colspan="1" rowspan="1">248 (45.7&#8201;%)</td><td align="left" colspan="1" rowspan="1">25,787 (49.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">33,644 (58.9&#8201;%)</td><td align="char" colspan="1" rowspan="1">0.117</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Number of lab/pathology tests (mean, SD)</td><td align="left" colspan="1" rowspan="1">6.8 (20.5)</td><td align="left" colspan="1" rowspan="1">7.9 (29)</td><td align="left" colspan="1" rowspan="1">8.2 (26.1)</td><td align="char" colspan="1" rowspan="1">0.388</td><td align="char" colspan="1" rowspan="1">0.226</td></tr><tr><td colspan="1" rowspan="1">Radiology</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 radiology exam (n, %)</td><td align="left" colspan="1" rowspan="1">52 (9.6&#8201;%)</td><td align="left" colspan="1" rowspan="1">8488 (16.1&#8201;%)</td><td align="left" colspan="1" rowspan="1">14,186 (24.8&#8201;%)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Number of radiology exams (mean, SD)</td><td align="left" colspan="1" rowspan="1">0.2 (0.6)</td><td align="left" colspan="1" rowspan="1">0.3 (1.2)</td><td align="left" colspan="1" rowspan="1">0.6 (1.8)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><underline>Outpatient pharmacy</underline></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;&#8201;1 pharmacy claim (n, %)</td><td align="left" colspan="1" rowspan="1">543 (100.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">52,569 (100.0&#8201;%)</td><td align="left" colspan="1" rowspan="1">57,125 (100.0&#8201;%)</td><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Number of pharmacy claims (mean, SD)</td><td align="left" colspan="1" rowspan="1">16.0 (15.2)</td><td align="left" colspan="1" rowspan="1">26.2 (21.1)</td><td align="left" colspan="1" rowspan="1">23.0 (21.1)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1"><bold>Costs per patient (mean, SD)</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">$12,995 ($15,184)</td><td align="left" colspan="1" rowspan="1">$8733 ($21,538)</td><td align="left" colspan="1" rowspan="1">$13,623 ($34,401)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">0.671</td></tr><tr><td colspan="1" rowspan="1">Inpatient</td><td align="left" colspan="1" rowspan="1">$282 ($2147)</td><td align="left" colspan="1" rowspan="1">$1404 ($12,536)</td><td align="left" colspan="1" rowspan="1">$3336 ($20,211)</td><td align="char" colspan="1" rowspan="1">0.037</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">Outpatient medical</td><td align="left" colspan="1" rowspan="1">$4183 ($8882)</td><td align="left" colspan="1" rowspan="1">$3868 ($12,403)</td><td align="left" colspan="1" rowspan="1">$7639 ($20,046)</td><td align="char" colspan="1" rowspan="1">0.555</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td colspan="1" rowspan="1">ER</td><td align="left" colspan="1" rowspan="1">$573 ($2005)</td><td align="left" colspan="1" rowspan="1">$627 ($2012)</td><td align="left" colspan="1" rowspan="1">$792 ($2599)</td><td align="char" colspan="1" rowspan="1">0.534</td><td align="char" colspan="1" rowspan="1">0.051</td></tr><tr><td colspan="1" rowspan="1">Physician office visit</td><td align="left" colspan="1" rowspan="1">$473 ($1827)</td><td align="left" colspan="1" rowspan="1">$743 ($4664)</td><td align="left" colspan="1" rowspan="1">$1210 ($5702)</td><td align="char" colspan="1" rowspan="1">0.178</td><td align="char" colspan="1" rowspan="1">0.003</td></tr><tr><td colspan="1" rowspan="1">Laboratory/pathology tests</td><td align="left" colspan="1" rowspan="1">$492 ($2314)</td><td align="left" colspan="1" rowspan="1">$363 ($1365)</td><td align="left" colspan="1" rowspan="1">$437 ($1602)</td><td align="char" colspan="1" rowspan="1">0.029</td><td align="char" colspan="1" rowspan="1">0.426</td></tr><tr><td colspan="1" rowspan="1">Radiology</td><td align="left" colspan="1" rowspan="1">$76 ($483)</td><td align="left" colspan="1" rowspan="1">$109 ($619)</td><td align="left" colspan="1" rowspan="1">$221 ($1107)</td><td align="char" colspan="1" rowspan="1">0.216</td><td align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td colspan="1" rowspan="1">Pharmacy</td><td align="left" colspan="1" rowspan="1">$8531 ($11,540)</td><td align="left" colspan="1" rowspan="1">$3461 ($9149)</td><td align="left" colspan="1" rowspan="1">$2649 ($9424)</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: BUP-TM=&#8201; transmucosal buprenorphine; BUP-XR=&#8201; extended-release buprenorphine; ER=&#8201; emergency room; HCRU=&#8201; healthcare resource utilization; OUD=&#8201; opioid use disorder; SD=&#8201; standard deviation</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec0085"><label>4</label><title>Discussion</title><p id="p0140">This study examined the association of demographic and clinical characteristics on ER visits among patients with OUD to gain insights that will help healthcare providers (HCPs), policymakers, and researchers devise evidence-based strategies to prevent the number of OUD related emergency events, enhance the quality of care, and reduce the impact of the opioid crisis. We found that any buprenorphine treatment, particularly extended-release buprenorphine, was associated with lower odds of all-cause ER visits compared to patients with no MOUD. Other factors influencing ER visits included history of a previous opioid overdose ER visit in the baseline period, demographics, gender, comorbidities, as well as later index years. Although patients in the BUP-XR group had similar all-cause healthcare costs compared to patients with no MOUD, BUP-XR patients had significantly lower inpatient and outpatient medical costs.</p><sec id="sec0090"><label>4.1</label><title>MOUD and risk of Overdose-Related Hospitalization/ER visits</title><p id="p0145">Our findings align with existing research demonstrating the potential influence of MOUD in reducing ER utilization. A retrospective cohort study assessing patients who were diagnosed with OUD between 2018 and 2019 (N&#8201;=&#8201;145,317) found that only 10.4&#8201;% of patients received MOUD prescriptions in the 12 months after diagnosis (<xref rid="bib2" ref-type="bibr">Bahrami et al., 2023</xref>). At one-year follow-up, the incidence of drug overdose-related hospitalization or ER visits varied by type of MOUD prescribed: naltrexone (14.3&#8201;%), methadone (12.3&#8201;%), and any buprenorphine (10.2&#8201;%). After adjustment for demographics/comorbidities, those who received buprenorphine prescriptions had a 16&#8201;% lower risk of drug overdose-related hospitalization or ER visit compared to methadone (<xref rid="bib2" ref-type="bibr">Bahrami et al., 2023</xref>). The findings from both previous literature and the current study reinforce the growing body of evidence supporting the effectiveness of MOUD in mitigating ER utilization.</p></sec><sec id="sec0095"><label>4.2</label><title>History of Non-fatal overdose and risk of subsequent ER visits</title><p id="p0150">In assessing the predictors for the four types of ER visits, our study found that patient&#8217;s history of having &#8805;&#8201;1 opioid overdose ER visit in the 6-month baseline period was a strong indicator for subsequent ER opioid overdose visits, as well as all-cause ER visits in the post-index period. Comparably, in a retrospective cohort study consisting of 16 ERs, researchers found 14.9&#8201;% of patients had a repeat overdose following an initial overdose, with 29&#8201;% of them experiencing it within 30 days of the initial overdose (<xref rid="bib17" ref-type="bibr">Suffoletto and Zeigler, 2020</xref>). In a self-reported patient survey study, results showed that p<bold>eople who inject drugs</bold> with a history of a prior overdose had higher odds of experiencing another overdose (OR: 28.58, CI; 14.10&#8211;57.96) (<xref rid="bib6" ref-type="bibr">Coffin et al., 2007</xref>). Lastly, in a Canadian prospective cohort study, results demonstrated that recent non-fatal overdose was independently associated with time to subsequent overdoses that were fatal (adjusted hazard ratio: 1.95, CI: 1.17&#8211;3.27) (<xref rid="bib3" ref-type="bibr">Caudarella et al., 2016</xref>). Findings from existing literature, as well as our study, offer evidence that an initial non-fatal overdose represents a critical point in time to initiate interventions.</p></sec><sec id="sec0100"><label>4.3</label><title>Special population considerations</title><p id="p0155">Prior research revealed the existence of risk factors among patients with opioid-related disorders presenting to the ER (<xref rid="bib16" ref-type="bibr">Sidlak et al., 2023</xref>, <xref rid="bib18" ref-type="bibr">Taylor et al., 2023</xref>). Both the current study and past literature found similar variables that were associated with higher risk of drug overdose-related hospitalization of ER visits, such as chronic conditions and substance use disorders (<xref rid="bib16" ref-type="bibr">Sidlak et al., 2023</xref>, <xref rid="bib18" ref-type="bibr">Taylor et al., 2023</xref>). An analysis of electronic health record (EHR) data and clinical notes from opioid-related patient presentations to the ER from 2013&#8211;2020 (N&#8201;=&#8201;82,577) in the US revealed topics related to SUD, chronic conditions, mental health, and medical management (<xref rid="bib18" ref-type="bibr">Taylor et al., 2023</xref>). Nine distinct cohorts of patient presentations that have different patient-oriented outcomes were reported with one-year survival rates ranging from 84.2&#8211;96.8&#8201;%, rates of one-year ER returns ranging from 9&#8211;34&#8201;%, rates of one-year opioid events (presumably related to opioid misuse or adverse events) ranging from 10&#8211;17&#8201;%, and rates of MOUD prescription (ranging from 1&#8201;% to 3&#8201;% for buprenorphine, 17&#8201;%-43&#8201;% for ordered and dispensed methadone treatment programs, and 11&#8201;%-16&#8201;% for naloxone) (<xref rid="bib18" ref-type="bibr">Taylor et al., 2023</xref>).</p><p id="p0160">Our findings align with previous research highlighting the disproportionate impact of opioid-related emergencies in specific populations. This underscores the importance of identification of risk factors to help tailor healthcare responses to address this issue among high-risk populations.</p></sec><sec id="sec0105"><label>4.4</label><title>Limitations</title><p id="p0165">This study has several limitations, primarily stemming from its retrospective cohort design and reliance on open-source databases with access to non-fatal overdoses, with limited visibility into healthcare activity beyond the facilities included in the database. Another limitation is the selection criteria requiring data linkage across the selected databases, which could introduce selection bias by excluding patients without complete data. The sample size experienced notable reductions when we required participants have &#8805;&#8201;1 Dx and LRx claim each, and during linkage with the CDM. We also required that participants have a stable pharmacy data source, which may lead to selection bias as our participants may have greater stability overall that would reduce their risk of opioid overdose compared to those without stable pharmacies and prescribing. Furthermore, excluding patients from the cohorts that had both BUP-XR and BUP-TM could lead to exclusion of patients who are less responsive to treatment. While these patients were excluded to focus on the distinct effects of BUP-XR and BUP-TM, it may have impacted the findings by underestimating the variability in outcomes.</p><p id="p0170">The study period overlaps with significant policy changes regarding the Drug Addiction Treatment Act waiver requirements and the COVID-19 pandemic. Between December 29th, 2021 and June 27th, 2023, the Drug Addiction Treatment Act waiver requirement, which required healthcare providers to undergo special training and obtain certification before prescribing buprenorphine, was eliminated (<xref rid="bib9" ref-type="bibr">2021</xref>). Although recent evidence indicates that neither the relaxation nor removal of the waiver had meaningful impact on buprenorphine prescribing (<xref rid="bib14" ref-type="bibr">Savitz et al., 2024</xref>, <xref rid="bib5" ref-type="bibr">Chua et al., 2024</xref>), these regulatory shifts, combined with disruptions in healthcare delivery during the COVID-19 pandemic, may have influenced patient&#8217;s access to treatment and the impact the study&#8217;s findings.</p><p id="p0175">The study is also limited by the sample size disparities across cohorts. The cohorts for patients initiating BUP-TM (n&#8201;=&#8201;57,125) and patients with no MOUD (n&#8201;=&#8201;52,569) were ~100-fold larger in size than the cohort initiating BUP-XR (n&#8201;=&#8201;543), which may compromise conclusions that can be drawn from comparing the small BUP-XR cohort with the larger cohorts. Additionally, based on the baseline demographic and clinical characteristics, the BUP-XR cohort was significantly different to other cohorts in factors such as age, gender and comorbidities. These differences may have influenced the observed results, introducing potential bias into the comparisons. While these demographic and clinical characteristics were statistically adjusted for in the logistic regression models, residual confounding cannot be entirely ruled out. For instance, we did not have information available on race or ethnicity in these linked databases, which may bias findings.</p><p id="p0180">Lastly, the 6-month observation period could be a limitation for patient costs, since it could exclude long-term treatments beyond 6 months. Pharmacy cost from prescriptions is not always populated accurately by suppliers and can be inflated if only the list price is provided. Patients who died during the study period were excluded from analysis; therefore, the sample may be biased towards a healthier population. The length of treatment was not assessed for any treatment cohort. In addition, synthetic opioid overdoses may be underreported as there may be variances in clinical documentation, such as categorizing synthetic overdoses under the broader category of opioid overdoses.</p></sec></sec><sec id="sec0110"><label>5</label><title>Conclusions</title><p id="p0185">In summary, this study provides valuable insights into the factors associated with ER visits among patients with OUD. Our findings demonstrate the potential benefits of buprenorphine treatment, particularly extended-release buprenorphine (BUP-XR) in reducing ER utilization. Specific subgroups, including individuals with history of opioid-related overdoses or certain comorbidities, remain at higher risk.</p><p id="p0190">Addressing underlying risk factors can help improve patient outcomes and reduce the strain on healthcare systems. Further research should be conducted on developing targeted interventions that address the specific needs of these vulnerable populations and exploring the long-term benefits of buprenorphine treatment.</p></sec><sec id="sec0115"><title>CRediT authorship contribution statement</title><p id="p0195"><bold>Swapna Munnangi:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Methodology, Formal analysis, Data curation. <bold>Mitch DeKoven:</bold> Writing &#8211; review &amp; editing, Supervision, Methodology, Formal analysis, Data curation. <bold>Yifan Gu:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Methodology, Formal analysis, Data curation. <bold>Robert Dunne:</bold> Writing &#8211; review &amp; editing, Validation, Supervision. <bold>Gaiazov Sabrina A:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Validation, Supervision, Resources, Project administration, Methodology, Funding acquisition, Conceptualization. <bold>Ann Wheeler:</bold> Writing &#8211; review &amp; editing, Supervision, Resources, Methodology, Funding acquisition, Conceptualization. <bold>William Mullen:</bold> Writing &#8211; review &amp; editing, Supervision, Resources, Methodology, Funding acquisition, Conceptualization.</p></sec><sec id="sec0120"><title>Relationship with funding organization</title><p id="p0200">The corresponding author is an employe of <funding-source id="spnsr1">Indivior Inc.</funding-source>, which funded the research.</p></sec><sec id="sec0125"><title>Role of funding source</title><p id="p0205">This research was funded by Indivior, Inc. The funding organization had no role in the data collection, management, and analysis of data.</p></sec><sec sec-type="COI-statement" id="coi0005"><title>Declaration of Competing Interest</title><p id="p0210">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Swapna Munnangi, PhD reports financial support was provided by Indivior Inc. Yifan Gu reports financial support was provided by Indivior Inc. Mitch DeKoven, MHSA reports financial support was provided by Indivior Inc. Sabrina Gaiazov, MPH reports a relationship with Indivior Inc that includes: employment. William Mullen, MPH, PA-C reports a relationship with Indivior Inc that includes: employment. Ann Wheeler, PharmD reports a relationship with Indivior Inc that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><element-citation publication-type="book" id="sbref0005"><person-group person-group-type="author"><name name-style="western"><surname>Allison</surname><given-names>P.D.</given-names></name></person-group><part-title>Convergence failures in logistic regression <underline>sas global</underline></part-title><source>Forum 2008</source><year>2008</year><publisher-name>SAS Institute Inc</publisher-name><publisher-loc>Cary, NC</publisher-loc></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Bahrami</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Digbeu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Raji</surname><given-names>M.A.</given-names></name></person-group><article-title>"Association of Medication-Assisted therapy and risk of drug Overdose-Related hospitalization or emergency room visits in patients with opioid use disorder."</article-title><source>Cureus</source><volume>15</volume><issue>8</issue><year>2023</year><object-id pub-id-type="publisher-id">e44167</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.44167</pub-id><pub-id pub-id-type="pmcid">PMC10519365</pub-id><pub-id pub-id-type="pmid">37753052</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Caudarella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Milloy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name></person-group><article-title>"Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs."</article-title><source>Drug Alcohol Depend.</source><volume>162</volume><year>2016</year><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">26993373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2016.02.024</pub-id><pub-id pub-id-type="pmcid">PMC4833586</pub-id></element-citation></ref><ref id="bib4"><mixed-citation publication-type="other" id="othref0005">Centers for Disease Control and Prevention (2022). Vital Statistics Rapid Release - Provisional Drug Overdose Data.</mixed-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Bicket</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A.S.B.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lagisetty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.D.</given-names></name></person-group><article-title>"Buprenorphine dispensing after elimination of the waiver requirement</article-title><source>N. Engl. J. Med</source><volume>390</volume><issue>16</issue><year>2024</year><fpage>1530</fpage><lpage>1532</lpage><pub-id pub-id-type="pmid">38657250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2312906</pub-id><pub-id pub-id-type="pmcid">PMC11103581</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Coffin</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bucciarelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ompad</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vlahov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galea</surname><given-names>S.</given-names></name></person-group><article-title>"Identifying injection drug users at risk of nonfatal overdose</article-title><source>Acad. Emerg. Med</source><volume>14</volume><issue>7</issue><year>2007</year><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">17554010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1197/j.aem.2007.04.005</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Cowan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Coupet</surname><given-names>E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Fiellin</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Hawk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Herring</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huntley</surname><given-names>K.</given-names></name><name name-style="western"><surname>McCormack</surname><given-names>R.</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>G.</given-names></name></person-group><article-title>"National institute on drug abuse clinical trials network meeting report: advancing emergency department initiation of buprenorphine for opioid use disorder</article-title><source>Ann. Emerg. Med</source><volume>82</volume><issue>3</issue><year>2023</year><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">37178101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annemergmed.2023.03.025</pub-id><pub-id pub-id-type="pmcid">PMC10524880</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>O.J.</given-names></name></person-group><article-title>"Multiple comparisons among means</article-title><source>J. Am. Stat. Assoc.</source><volume>56</volume><issue>293</issue><year>1961</year><fpage>52</fpage><lpage>64</lpage></element-citation></ref><ref id="bib9"><mixed-citation publication-type="other" id="othref0010">February 25). "S.445 - 117th Congress (2021-2022): Mainstreaming Addiction Treatment Act of 2021." from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.congress.gov/bill/117th-congress/senate-bill/445" id="ir0010">&#9001;https://www.congress.gov/bill/117th-congress/senate-bill/445&#9002;</ext-link>.</mixed-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Stringfellow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>DiGennaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Poellinger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wakeman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>M.S.</given-names></name></person-group><article-title>"Opioid overdose decedent characteristics during COVID-19</article-title><source>Ann. Med</source><volume>54</volume><issue>1</issue><year>2022</year><fpage>1081</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">35467475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2022.2067350</pub-id><pub-id pub-id-type="pmcid">PMC9045762</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Hawk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ketcham</surname><given-names>E.</given-names></name><name name-style="western"><surname>LaPietra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stader</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>G.</given-names></name></person-group><article-title>"Consensus recommendations on the treatment of opioid use disorder in the emergency department</article-title><source>Ann. Emerg. Med</source><volume>78</volume><issue>3</issue><year>2021</year><fpage>434</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">34172303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annemergmed.2021.04.023</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Marsden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gilvarry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mitcheson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bisla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cape</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cowden</surname><given-names>F.</given-names></name><name name-style="western"><surname>Day</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dewhurst</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hearn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lowry</surname><given-names>N.</given-names></name><name name-style="western"><surname>McCusker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>R.</given-names></name><name name-style="western"><surname>Myton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quarshie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanderwaal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wareham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoare</surname><given-names>Z.</given-names></name></person-group><article-title>Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial</article-title><source>EClinicalMedicine</source><volume>66</volume><year>2023</year><object-id pub-id-type="publisher-id">102311</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102311</pub-id><pub-id pub-id-type="pmcid">PMC10692661</pub-id><pub-id pub-id-type="pmid">38045803</pub-id></element-citation></ref><ref id="bib13"><mixed-citation publication-type="other" id="othref0015">Romano, P.S., L.L. Roos and J.G. Jollis (1993). "Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives." J Clin Epidemiol <bold>46</bold>(10): 1075-1079; discussion 1081-1090.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0895-4356(93)90103-8</pub-id><pub-id pub-id-type="pmid">8410092</pub-id></mixed-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Savitz</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>B.</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melnick</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Jeffery</surname><given-names>M.M.</given-names></name></person-group><article-title>"Trends in the prescribing of buprenorphine for opioid use disorder, 2019-2023</article-title><source>Mayo Clin. Proc. Innov. Qual. Outcomes</source><volume>8</volume><issue>3</issue><year>2024</year><fpage>308</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">38841599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocpiqo.2024.04.004</pub-id><pub-id pub-id-type="pmcid">PMC11152959</pub-id></element-citation></ref><ref id="bib15"><mixed-citation publication-type="other" id="othref0020">Schiller, E.Y., A. Goyal and O.J. Mechanic (2023). Opioid Overdose. StatPearls. Treasure Island (FL).</mixed-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Sidlak</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dibble</surname><given-names>B.</given-names></name></person-group><article-title>"Increasing number and shifting demographics of adolescent opioid use disorder presentations to the emergency department."</article-title><source>Am. J. Emerg. Med</source><volume>73</volume><year>2023</year><fpage>79</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">37625340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2023.08.011</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Suffoletto</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zeigler</surname><given-names>A.</given-names></name></person-group><article-title>"Risk and protective factors for repeated overdose after opioid overdose survival."</article-title><source>Drug Alcohol Depend.</source><volume>209</volume><year>2020</year><object-id pub-id-type="publisher-id">107890</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2020.107890</pub-id><pub-id pub-id-type="pmcid">PMC7127977</pub-id><pub-id pub-id-type="pmid">32058246</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gilson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>K.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coppi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chartash</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fiellin</surname><given-names>D.</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>G.</given-names></name></person-group><article-title>"Computational phenotypes for patients with opioid-related disorders presenting to the emergency department."</article-title><source>PLoS One</source><volume>18</volume><issue>9</issue><year>2023</year><object-id pub-id-type="publisher-id">e0291572</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0291572</pub-id><pub-id pub-id-type="pmcid">PMC10503758</pub-id><pub-id pub-id-type="pmid">37713393</pub-id></element-citation></ref></ref-list><sec id="sec0135" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary material</title><p id="p0225">
<supplementary-material content-type="local-data" id="ec0005" position="float" orientation="portrait"><caption><p>Supplementary material</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0005"><title>Acknowledgements</title><p id="p0215">Special acknowledgements to Jamie Lo, MPH, PhD, for her assistance in formatting and editorial support.</p></ack><fn-group><fn id="sec0130" fn-type="supplementary-material"><label>Appendix A</label><p id="p0220">Supplementary data associated with this article can be found in the online version at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.dadr.2025.100349" id="ir0005">doi:10.1016/j.dadr.2025.100349</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>